Curevac abandons Covid shot as trials disappoint

Curevac NV said on Tuesday it will give up on its firstgeneration Covid-19 vaccine candidate and instead focus on collaborating with GSK to develop improved MRNA vaccine technology. The German biotechnology company's shares were off about 8 per cent after earlier plunging as much as 13%, hitting their lowest since going public in August last year. Curevac said it would abandon its application for approval from the European Medicines Agency for its first Covid-19 vaccine candidate, CVNCOV, after late-stage trials delivered disappointing results in June with 47 per cent efficacy.